

Package: p2oncology (via r-universe)

September 15, 2026

Title Single Arm Phase 2 Oncology Trial R Code Library

Version 0.1

Description Single arm phase 2 oncology trial.

License MIT + file LICENSE

Encoding UTF-8

Roxygen list(markdown = TRUE)

RoxygenNote 8.0.0

Imports foreach, dplyr, jsonlite

Depends clinfun, mvtnorm, doParallel

NeedsCompilation no

Author Ping Gao [aut, cre]

Maintainer Ping Gao <ping.gao@innovatiostat.com>

Repository <https://innovatiostat.r-universe.dev>

Date/Publication 2026-08-09 11:55:43 UTC

RemoteUrl <https://github.com/innovatiostat/rcode>

RemoteRef HEAD

RemoteSha f07909e49166899ce1ea4cc49072ac6d094bba95

RemoteSubdir p2oncology

Contents

asd_ci_est_one_arm_2_stage	2
asd_ci_est_one_arm_3_stage	3
EXP_3_stg_sz	4
gsd_ci_est_2_stage	6
gsd_ci_est_3_stage	7
hybrid_sz	8
interim_analysis	9
midpnt_sz	10
one_arm_ad_3_stg_binary	11

one_arm_ad_two_stg_binary	13
one_arm_rej_2_stg_binary	15
one_arm_rej_3_stg_binary	16
one_arm_rej_simon_binary	17
simon_ph2_sz	18
Index	20

asd_ci_est_one_arm_2_stage
<i>Final analysis: two stage design, with sample size change</i>

Description

Final analysis: two stage design, with sample size change

Usage

asd_ci_est_one_arm_2_stage(p_0, n_1, n_2, r_1_e, r_2, n_new, x_1, x_new, alpha)

Arguments

p_0	Response rate indicating low activity with insufficient clinical benefit.
n_1	Number of patients at first look.
n_2	Number of patients at second look.
r_1_e	The trial would be stopped for superiority if at least r_1_e responses are observed at the first look.
r_2	If no more than r_2 responses are observed at the second look, then the null hypothesis will not be rejected.
n_new	New sample size after the interim analysis.
x_1	Number of responses at the first look.
x_new	Number of responses at the final visit.
alpha	One-sided type I error.

Value

UL: upper limit of confidence interval.
LL: lower limit of confidence interval.
The results with continuity correction are not necessarily different from those with continuity correction.
The need for continuity correction can be determined through simulations on type I error (see Gao, Zhang, 2004).

References

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
asd_ci_est_one_arm_2_stage( p_0=0.2,n_1=100,n_2=105,r_1_e=33,r_2=29,n_new=115,
x_1=28,x_new=34,alpha=0.025)
```

```
asd_ci_est_one_arm_3_stage
```

Final analysis: three stage design, with sample size change

Description

Final analysis: three stage design, with sample size change

Usage

```
asd_ci_est_one_arm_3_stage(
  p_0,
  n_2,
  n_3,
  r_2_e,
  r_2,
  r_3,
  n_new,
  x_2,
  x_new,
  alpha
)
```

Arguments

<code>p_0</code>	Response rate indicating low activity with insufficient clinical benefit.
<code>n_2</code>	Number of patients at second look.
<code>n_3</code>	Number of patients at third look.
<code>r_2_e</code>	The trial would be stopped for superiority if at least <code>r_2_e</code> responses are observed at the second look. If <code>r_2_e</code> was not used in the design, enter NA.

r_2	If no more than r_2 responses are observed at the second look, then the trial would be stopped for futility.
r_3	If no more than r_3 responses are observed at the third look, then the null hypothesis will not be rejected.
n_new	New sample size after the interim analysis (at the second look).
x_2	Number of responses at the second look.
x_new	Number of responses at the final visit.
alpha	One-sided type I error.

Value

UL: upper limit of confidence interval.
LL: lower limit of confidence interval.
The results with continuity correction are not necessarily different from those with continuity correction.
The need for continuity correction can be determined through simulations on type I error (see Gao, Zhang, 2004).

References

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon’s design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.
Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
asd_ci_est_one_arm_3_stage( p_0=0.2,n_2=105,n_3=110,r_2_e=33,r_3=29,n_new=115,  
x_2=28,x_new=34,alpha=0.025)
```

EXP_3_stg_sz	Three-stage design
--------------	--------------------

Description

Three-stage design

Usage

```
EXP_3_stg_sz(alpha, beta, p_0, p_low, p_1, d_23_cut)
```

Arguments

<code>alpha</code>	One-sided type I error.
<code>beta</code>	Type II error.
<code>p_0</code>	Response rate indicating low activity with insufficient clinical benefit.
<code>p_low</code>	Minimally clinically beneficial response rate.
<code>p_1</code>	Assumed response rate.
<code>d_23_cut</code>	$\text{Min}(n_3 - n_2)$ sets the minimal difference between n_3 and n_2 for the design.

Value

`n1`: Number of patients at first look. `n1` for the three-stage design is the from Simon's design with $p = p_1$.

`n_2`: Number of patients at second look. `n_2` for the three-stage design is the `n1` from Simon's design with $p = p_{\text{low}}$.

`r1`: If no more than `r1` responses are observed at the first look, then the trial would be stopped for futility.

`r_2`: The null hypothesis will be rejected if at least `r_2` responses are observed at the end of the trial.

$\text{EN}(p_0)$ is the expected sample size under the null hypothesis.

$\text{PET}(p_0)$ is the probability of early termination under the null hypothesis.

PET_p is the probability of early termination under $p = p_1$.

$\text{PET}_{p_{\text{low}}}$ is the probability of early termination under $p = p_{\text{low}}$.

power_{p_1} is the power under $p = p_1$.

$\text{power}_{p_{\text{low}}}$ is the power under $p = p_{\text{low}}$.

Type I error is the probability of rejecting the null hypothesis under $p \leq p_0$.

The minimax design has the smallest `n_2` among all possible choices of (n_1, r_1, n_2, r_2) .

The optimal design has the smallest $\text{EN}(p_0)$ among all possible choices of (n_1, r_1, n_2, r_2) .

The `n1` and `n_2` for the average design is the average of `n1`'s and `n_2`'s from the minimax and the optimal designs.

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. *Controlled Clinical Trials* 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, *Journal of Biopharmaceutical Statistics*, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.

Examples

```
## Not run:
EXP_3_stg_sz(alpha=c(0.001,0.024),beta=0.1,p_0=0.2,p_low=0.33,p_1=0.4,d_23_cut=5)

## End(Not run)
```

gsd_ci_est_2_stage	<i>Final analysis: two stage design, no sample size change</i>
--------------------	--

Description

Final analysis: two stage design, no sample size change

Usage

```
gsd_ci_est_2_stage(p_0, n_1, n_2, r_1_e, r_2, x_last, last_vt, alpha)
```

Arguments

<code>p_0</code>	Response rate indicating low activity with insufficient clinical benefit.
<code>n_1</code>	Number of patients at first look.
<code>n_2</code>	Number of patients at second look.
<code>r_1_e</code>	The trial would be stopped for superiority if at least <code>r2e</code> responses are observed at the second look.
<code>r_2</code>	If no more than <code>r_2</code> responses are observed at the second look, then the null hypothesis will not be rejected.
<code>x_last</code>	Number of responses at the final visit.
<code>last_vt</code>	1.
<code>alpha</code>	One-sided type I error.

Value

UL: upper limit of confidence interval.

LL: lower limit of confidence interval.

The results with continuity correction are not necessarily different from those with continuity correction.

The need for continuity correction can be determined through simulations on type I error (see Gao, Zhang, 2004).

References

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon’s design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
gsd_ci_est_2_stage(p_0=0.2,n_1=100,n_2=105,r_1_e=NA,r_2=29,x_last=31,last_vt=1,alpha=0.025)
```

gsd_ci_est_3_stage	<i>Final analysis: three stage design, no sample size change</i>
--------------------	--

Description

Final analysis: three stage design, no sample size change

Usage

```
gsd_ci_est_3_stage(p_0, n_2, n_3, r_2_e, r_3, x_last, last_vt, alpha)
```

Arguments

p_0	Response rate indicating low activity with insufficient clinical benefit.
n_2	Number of patients at second look.
n_3	Number of patients at third look.
r_2_e	The trial would be stopped for superiority if at least r_2_e responses are observed at the second look. If r_2_e was not used in the design, enter NA.
r_3	If no more than r_3 responses are observed at the third look, then the null hypothesis will not be rejected.
x_last	Number of responses at the final visit.
last_vt	1.
alpha	One-sided type I error.

Value

UL: upper limit of confidence interval.

LL: lower limit of confidence interval.

The results with continuity correction are not necessarily different from those with continuity correction.

The need for continuity correction can be determined through simulations on type I error (see Gao, Zhang, 2004).

References

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon’s design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
gsd_ci_est_3_stage(p_0=0.2,n_2=100,n_3=105,r_2_e=31,r_3=29,x_last=31,last_vt=3,alpha=0.025)
```

hybrid_sz	<i>Two-stage design: the hybrid design</i>
-----------	--

Description

Two-stage design: the hybrid design

Usage

```
hybrid_sz(alpha, beta, p_0, p_low, p_1, d_12_cut)
```

Arguments

- alpha One-sided type I error.
- beta Type II error.
- p_0 Response rate indicating low activity with insufficient clinical benefit.
- p_low Minimally clinically beneficial response rate.
- p_1 Assumed response rate.
- d_12_cut Min(n2-n1) sets the minimal difference between n2 and n1 for the design.

Value

- n1: Number of patients at first look.
- n_2: Number of patients at second look. n_2 is also the total sample size.
- r1: If no more than r1 responses are observed at the first look, then the trial would be stopped for futility.
- r_2: The null hypothesis will be rejected if at least r_2 responses are observed at the end of the trial.
- EN(p0) is the expected sample size under the null hypothesis.
- PET(p0) is the probability of early termination under the null hypothesis.
- PET_p is the probability of early termination under p=p_1.

PET_p_low is the probability of early termination under $p=p_low$.
power_p is the power under $p=p_1$.
power_p_low is the power under $p=p_low$.
Type I error is the probability of rejecting the null hypothesis under $p \leq p_0$.
The minimax design has the smallest n_2 among all possible choices of (n_1, r_1, n_2, r_2) .
The optimal design has the smallest $EN(p_0)$ among all possible choices of (n_1, r_1, n_2, r_2) .
The n_1 for the average design is the average of n_1 's from the minimax and the optimal designs.

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).
P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon’s design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.

Examples

```
hybrid_sz(alpha=c(0.001,0.024),beta=0.1,p_0=0.2,p_low=0.4,p_1=0.55,d_12_cut=0)
```

interim_analysis	<i>The interim analysis can be conducted for both two-stage and three-stage designs</i>
------------------	---

Description

The interim analysis can be conducted for both two-stage and three-stage designs

Usage

```
interim_analysis(p_0, r_final, n_inter, n_final, x_inter, beta, N_max)
```

Arguments

p_0	Response rate indicating low activity with insufficient clinical benefit.
r_final	For two-stage designs, $r_final=r_2$. For the three-stage design, $r_final=r_3$.
n_inter	Number of patients at the interim look. For two-stage designs, $n_inter=n_1$. For the three-stage design, $n_inter=n_2$.
n_final	For two-stage designs, $n_inter=n_2$. For the three-stage design, $n_inter=n_3$.
x_inter	Number of responses observed at the interim look.
beta	The conditional type II error. $1-beta$ is the desired conditional power.
N_max	Pre-selected maximum sample size.

Value

n_new: is the new sample size.

r_new (without continuity correction) and r_new (with continuity correction) are thresholds such that the null hypothesis will be rejected at n_new if at least r_new responses are observed. Simulations on type I error will help to determine if continuity correction is needed.

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon’s design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.

P. Gao, J.H. Ware, C. Mehta, (2008), Sample size re-estimation for adaptive sequential designs. Journal of Biopharmaceutical Statistics, 18: 1184–1196, 2008.

Examples

```
interim_analysis(p_0=0.2,r_final=17,n_inter=22,n_final=56,x_inter=7,beta=0.1,N_max=120)
```

midpnt_sz	<i>Two-stage design: the midpoint design</i>
-----------	--

Description

Two-stage design: the midpoint design

Usage

```
midpnt_sz(alpha, beta, p_0, p_low, p_1, q, d_12_cut)
```

Arguments

- | | |
|----------|---|
| alpha | One-sided type I error. |
| beta | Type II error. |
| p_0 | Response rate indicating low activity with insufficient clinical benefit. |
| p_low | Minimally clinically beneficial response rate. |
| p_1 | Assumed response rate. |
| q | $0 < q < 1$. |
| d_12_cut | Min(n2-n1) sets the minimal difference between n2 and n1 for the design. |

Value

n1: Number of patients at first look.

n_2: Number of patients at second look. n_2 is also the total sample size.

r1: If no more than r1 responses are observed at the first look, then the trial would be stopped for futility.

r_2: The null hypothesis will be rejected if at least r_2 responses are observed at the end of the trial.

EN(p0) is the expected sample size under the null hypothesis.

PET(p0) is the probability of early termination under the null hypothesis.

PET_p is the probability of early termination under $p=p_1$.

PET_p_low is the probability of early termination under $p=p_{low}$.

power_p is the power under $p=p_1$.

power_p_low is the power under $p=p_{low}$.

Type I error is the probability of rejecting the null hypothesis under $p \leq p_0$.

The minimax design has the smallest n_2 among all possible choices of (n1,r1,n2,r2).

The optimal design has the smallest EN(p_0) among all possible choices of (n1,r1,n_2,r_2).

The n1 for the average design is the average of n1's from the minimax and the optimal designs.

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.

Examples

```
midpnt_sz(alpha=c(0.001,0.024),beta=0.1,p_0=0.2,p_low=0.33,p_1=0.4,q=0.5,d_12_cut=5)
```

one_arm_ad_3_stg_binary

Simulations: adaptive three stage design

Description

Simulations: adaptive three stage design

Usage

```
one_arm_ad_3_stg_binary(
  p_1,
  p_0,
  n_1,
  r_1,
  n_2,
  r_2,
  r_2_e = NA,
  n_3,
  r_3,
  N_max,
  beta,
  sim_num
)
```

Arguments

<code>p_1</code>	The assumed response rate.
<code>p_0</code>	Response rate indicating low activity with insufficient clinical benefit.
<code>n_1</code>	Number of patients at first look.
<code>r_1</code>	If no more than <code>r_1</code> responses are observed at the first look, then the trial would be stopped for futility.
<code>n_2</code>	Number of patients at second look.
<code>r_2</code>	If no more than <code>r_2</code> responses are observed at the second look, then the trial would be stopped for futility.
<code>r_2_e</code>	The trial would be stopped for superiority if at least <code>r_2_e</code> responses are observed at the second look. If <code>r_2_e</code> is not used in the design, enter NA.
<code>n_3</code>	Number of patients at third look.
<code>r_3</code>	If no more than <code>r_3</code> responses are observed at the third look, then the null hypothesis will not be rejected.
<code>N_max</code>	Maximum sample size for the trial.
<code>beta</code>	Type II error. The target power is $1 - \text{beta}$.
<code>sim_num</code>	Purpose of simulation: To verify type I error control by setting <code>p_1 = p_0</code> , To evaluate the operating characteristics of the adaptive design and to determine if continuity correction is necessary.

Value

Average sample size is $EN(p_1)$.

Rate of termination is $PET(p_1)$

If rejection rate without continuity correction does not exceed `beta`, the continuity correction is not needed for this group of parameters `p_0, n_1, r_1, n_2, r_2, r_2_e, n_3, r_3`. Otherwise, continuity correction should be applied.

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.

P. Gao, J.H. Ware, C. Mehta, (2008), Sample size re-estimation for adaptive sequential designs. Journal of Biopharmaceutical Statistics, 18: 1184–1196, 2008.

Examples

```
## Not run:
one_arm_ad_3_stg_binary(p_1=0.2,p_0=0.2,n_1=37,r_1=8,n_2=100,r_2=22,r_2_e=33,
n_3=105,r_3=29,N_max=150,beta=0.1,sim_num=100000)

## End(Not run)
```

```
one_arm_ad_two_stg_binary
```

Simulations: adaptive two stage design

Description

Simulations: adaptive two stage design

Usage

```
one_arm_ad_two_stg_binary(
  p_1,
  p_0,
  n_1,
  r_1,
  r_1_e = NA,
  n_2,
  r_2,
  N_max,
  beta,
  sim_num
)
```

Arguments

p_1	The assumed response rate.
p_0	Response rate indicating low activity with insufficient clinical benefit.

<code>n_1</code>	Number of patients at first look.
<code>r_1</code>	If no more than <code>r_1</code> responses are observed at the first look, then the trial would be stopped for futility.
<code>r_1_e</code>	The trial would be stopped for superiority if at least <code>r_1_e</code> responses are observed at the first look. If <code>r_1_e</code> is not used in the design, enter NA.
<code>n_2</code>	Number of patients at second look.
<code>r_2</code>	If no more than <code>r_2</code> responses are observed at the second look, then the null hypothesis will be rejected.
<code>N_max</code>	Maximum sample size for the trial.
<code>beta</code>	Type II error. The target power is $1 - \text{beta}$.
<code>sim_num</code>	Purpose of simulation: To verify type I error control by setting <code>p_1=p_0</code> , To evaluate the operating characteristics of the adaptive design and to determine if continuity correction is necessary.

Value

Average sample size is $EN(p_1)$.

Rate of termination is $PET(p_1)$

If rejection rate without continuity correction does not exceed `alpha`, the continuity correction is not needed for this group of parameters `p_0,n_1,r_1,r_1_e,n_2,r_2`. Otherwise, continuity correction should be applied.

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.

P. Gao, J.H. Ware, C. Mehta, (2008), Sample size re-estimation for adaptive sequential designs. Journal of Biopharmaceutical Statistics, 18: 1184–1196, 2008.

Examples

```
## Not run:
one_arm_ad_two_stg_binary(p_1=0.2,p_0=0.2,n_1=37,r_1=9,r_1_e=NA,n_2=53,r_2=16,
N_max=140,beta=0.1,sim_num=100000)

## End(Not run)
```

one_arm_rej_2_stg_binary
<i>Simulations: Two stage fixed expanded Simon’s design: either hybrid or mid-point design</i>

Description

Simulations: Two stage fixed expanded Simon’s design: either hybrid or mid-point design

Usage

one_arm_rej_2_stg_binary(p_1, p_0, n_1, r_1_f, r_1_e = NA, n_2, r_2, sim_num)

Arguments

p_1	The assumed response rate.
p_0	Response rate indicating low activity with insufficient clinical benefit.
n_1	Number of patients at first look.
r_1_f	If no more than r_1 responses are observed at the first look, then the trial would be stopped for futility.
r_1_e	The trial would be stopped for superiority if at least r_1_e responses are observed at the first look. If r_1_e is not used in the design, enter NA.
n_2	Number of patients at second look.
r_2	If no more than r_2 responses are observed at the second look, then the null hypothesis will be rejected.
sim_num	Purpose of simulation: To verify type I error control by setting p_1=p_0, To verify the parameters n_1,r_1_f,r_1_e,n_2,r_2 are correctly chosen, such that the rejection rate matches that from the design table from either the hybrid design or the mid-point design.

Value

Average sample size is EN(p_1).
Rate of termination is PET(p_1)

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon’s design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.

P. Gao, J.H. Ware, C. Mehta, (2008), Sample size re-estimation for adaptive sequential designs. Journal of Biopharmaceutical Statistics, 18: 1184–1196, 2008.

Examples

```
## Not run:
one_arm_rej_2_stg_binary(p_1=0.2,p_0=0.2,n_1=100,r_1_f=25,r_1_e=33,
n_2=105,r_2=29,sim_num=100000)

## End(Not run)
```

```
one_arm_rej_3_stg_binary
```

*Simulations: Expanded Simon's design: the three stage design,
no sample size change*

Description

Simulations: Expanded Simon's design: the three stage design, no sample size change

Usage

```
one_arm_rej_3_stg_binary(
  p_1,
  p_0,
  n_1,
  r_1,
  n_2,
  r_2_f,
  r_2_e = NA,
  n_3,
  r_3,
  sim_num
)
```

Arguments

p_1	The assumed response rate.
p_0	Response rate indicating low activity with insufficient clinical benefit.
n_1	Number of patients at first look.
r_1	If no more than r_1 responses are observed at the first look, then the trial would be stopped for futility.
n_2	Number of patients at second look.
r_2_f	If no more than responses are observed at the second look, then the trial would be stopped for futility.
r_2_e	The trial would be stopped for superiority if at least r_2_e responses are observed at the first look. If r_2_e is not used in the design, enter NA.
n_3	Number of patients at third look.

<code>r_3</code>	If at least <code>r_2</code> responses are observed at the third look, then the null hypothesis will be rejected.
<code>sim_num</code>	Purpose of simulation: To verify type I error control by setting <code>p_1=p_0</code> , To verify the parameters <code>n_1,r_1,n_2,r_2_f,r_2_e,n_3,r_3</code> are correctly chosen, such that the rejection rate matches that from the design table of the three-stage design.

Value

Average sample size is $EN(p_1)$.

Rate of termination is $PET(p_1)$

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.

P. Gao, J.H. Ware, C. Mehta, (2008), Sample size re-estimation for adaptive sequential designs. Journal of Biopharmaceutical Statistics, 18: 1184–1196, 2008.

Examples

```
## Not run:
one_arm_rej_3_stg_binary(p_1=0.2,p_0=0.2,n_1=37,r_1=8,n_2=100,r_2_f=22,r_2_e=33,
n_3=105,r_3=29,sim_num=100000)

## End(Not run)
```

one_arm_rej_simon_binary

Simulations: two stage fixed Simon's design

Description

Simulations: two stage fixed Simon's design

Usage

```
one_arm_rej_simon_binary(p_1, p_0, n_1, r_1, n_2, r_2, sim_num)
```

Arguments

<code>p_1</code>	The assumed response rate.
<code>p_0</code>	Response rate indicating low activity with insufficient clinical benefit.
<code>n_1</code>	Number of patients at first look.
<code>r_1</code>	If no more than <code>r_1</code> responses are observed at the first look, then the trial would be stopped for futility.
<code>n_2</code>	Number of patients at second look.
<code>r_2</code>	If no more than <code>r_2</code> responses are observed at the second look, then the null hypothesis will be rejected.
<code>sim_num</code>	Purpose of simulation: To verify type I error control by setting <code>p_1=p_0</code> , To verify the parameters <code>n_1,r_1,n_2,r_2</code> are correctly chosen, such that the trial has $1 - \text{power}$ if the true response rate is <code>p_1</code> .

Value

Average sample size is $EN(p_1)$.

Rate of termination is $PET(p_1)$

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.

P. Gao, J.H. Ware, C. Mehta, (2008), Sample size re-estimation for adaptive sequential designs. Journal of Biopharmaceutical Statistics, 18: 1184–1196, 2008.

Examples

```
## Not run:
one_arm_rej_simon_binary(p_1=0.4,p_0=0.2,n_1=37,r_1=9,n_2=53,r_2=16,sim_num=100000)

## End(Not run)
```

simon_ph2_sz

Two-stage design: Simon's design

Description

Two-stage design: Simon's design

Usage

```
simon_ph2_sz(alpha, beta, p_0, p_1)
```

Arguments

alpha	One-sided type I error.
beta	Type II error.
p_0	Response rate indicating low activity with insufficient clinical benefit.
p_1	Assumed response rate.

Value

r1: If no more than **r1** responses are observed at the first look, then the trial would be stopped for futility.

n1: Number of patients at first look.

r_2: The null hypothesis will be rejected if at least **r_2** responses are observed at the end of the trial.

n_2: Number of patients at second look. **n_2** is also the total sample size.

EN(p_0) is the expected sample size under the null hypothesis.

PET(p_0) is the probability of early termination under the null hypothesis.

PET_p_1 is the probability of early termination under $p=p_1$.

power_p_1 is the power under $p=p_1$.

Type I error is the probability of rejecting the null hypothesis under $p \leq p_0$.

The minimax design has the smallest **n_2** among all possible choices of $(n1, r1, n_2, r_2)$.

The optimal design has the smallest **EN(p_0)** among all possible choices of $(n1, r1, n_2, r_2)$.

The average design is an augmentation of the original Simon's design (Gao, Zhang. 2024).

The **n1** for the average design is the average of **n1**'s from the minimax and the optimal designs.

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673>.

Examples

```
simon_ph2_sz(alpha=0.025,beta=0.1,p_0=0.2,p_1=0.33)
```

Index

asd_ci_est_one_arm_2_stage, [2](#)
asd_ci_est_one_arm_3_stage, [3](#)

EXP_3_stg_sz, [4](#)

gsd_ci_est_2_stage, [6](#)
gsd_ci_est_3_stage, [7](#)

hybrid_sz, [8](#)

interim_analysis, [9](#)

midpnt_sz, [10](#)

one_arm_ad_3_stg_binary, [11](#)
one_arm_ad_two_stg_binary, [13](#)
one_arm_rej_2_stg_binary, [15](#)
one_arm_rej_3_stg_binary, [16](#)
one_arm_rej_simon_binary, [17](#)

simon_ph2_sz, [18](#)